While ERα promotes proliferation and inflammation of prostate cancer cells, driving disease progression even after ADT, ERβ generally exhibits antiproliferative and pro-apoptotic effects that suppress tumor growth [38]. Here, ESR2 is linked to prostate carcinoma.